{"ATC Code":"N06AB08","Abbreviation":[],"Aliases":["Fluvoxamina","Fluvoxaminum","Dumirox","N06AB08","1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-","Nu Fluvoxamine","Novo Fluvoxamine","PMS Fluvoxamine","ratio Fluvoxamine","ratio-Fluvoxamine","Fluvoxamin","Geminis, Fluvoxamina","Fluvoxamin neuraxpharm","(2-aminoethoxy)((5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene))amine","(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine","2-((E)-(5-methoxy-1-(4-(trifluoromethyl)phenyl)pentylidene)amino)oxyethanamine","C15h21f3n2o2","1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,O-(2-aminoethyl)oxime, (1E)-","(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime","Cas-54739-18-3","FluvoxaMine?","5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime","1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-, O-(2-aminoethyl)oxime, (1E)-","Ncgc00018193-06","1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, o-(2-aminoethyl)oxime, (1e)-"],"Biological Half-Life":"15.6 hours.","CAS":"54739-18-3","ChEBI":"CHEBI:5138","ChEMBL":"CHEMBL814","ChemicalClasses":["alkylbenzene"],"Chirality":"achiral","Classes":["Serotonin reuptake inhibitor"],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin Uptake Inhibitors","Drug Indication":"Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.","Erowid Experience Reports":null,"Esters":[],"European Community (EC) Number":"611-193-1","FDA Pharmacological Classification":"O4L1XPO44W","Formating":[],"HeavyAtomCount":22,"Human Drugs":"Antidepressants -\u003e Selective serotonin reuptake inhibitors (SSRI)","IUPACName":"2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine","InChI":"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+","InChIKey":"CJOFXWAVKWHTFT-XSFVSMFZSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.","Melting Point":"120-121.5 °C","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eF\u003csub\u003e3\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"318.33 g/mol","Pharmacodynamics":"Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. \u003ci\u003eIn vitro\u003c/i\u003e studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Moreover, apart from binding to σ1 receptors, fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT\u003csub\u003e1A\u003c/sub\u003e, 5HT\u003csub\u003e1B\u003c/sub\u003e, 5HT\u003csub\u003e2\u003c/sub\u003e), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. Furthermore, some studies have demonstrated that the chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors (as has been observed with other drugs effective in the treatment of major depressive disorder), while others suggest the opposite.","PubChemId":5324346,"Record Description":["LiverTox|CNS|Antidepressant|SSRI"],"RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Fluvoxamine","Name":"Fluvoxamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00176","Name":"Fluvoxamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5324346","Name":"Fluvoxamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL814","Name":"Fluvoxamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5138","Name":"Fluvoxamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=54739-18-3","Name":"Fluvoxamine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07571","Name":"Fluvoxamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/O4L1XPO44W","Name":"Fluvoxamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID2044002","Name":"Fluvoxamine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5324346, Fluvoxamine. Accessed August 14, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5324346\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5324346\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Fluvoxamine. UNII: O4L1XPO44W. Global Substance Registration System. Accessed August 14, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/O4L1XPO44W\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/O4L1XPO44W\u003c/a\u003e"],"SMILES":"COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F","SaltData":[{"AcidCount":1,"AmineCount":1,"Formula":"O=C(O)CC(O)C(=O)O","Name":"maleate","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 236.461 110.658\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h237v111H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m147.107 63.97-9.92 5.727M130.625 69.694l-9.915-5.724M120.71 63.97l-13.198 7.62M107.512 71.59l-13.198-7.62M94.314 63.97l-13.198 7.62M81.116 71.59l-13.199-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M67.917 52.58v11.39M70.356 52.58v9.982\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M67.917 52.58v5.695M70.356 52.58v4.991\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m71.071 46.909 6.764-3.905M81.116 37.188V25.87M81.116 25.87l13.198-7.62M94.314 18.25V7.19M67.917 63.97l-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m54.719 71.59-13.203-7.629M52.281 72.997l-10.765-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m41.516 63.961-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.318 71.581.005 15.249M30.757 72.989l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.323 86.83 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m41.526 94.458 13.198-7.62M41.526 91.642l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.719 71.59.005 15.248M28.323 86.83l-13.199 7.62M15.124 94.45l5.554 9.619M15.124 94.45l-10.682 6.167M15.124 94.45 8.805 83.504\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M136.168 71.587q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M69.858 51.179h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732v2.738h-.565V46.28h.714l2.608 4.054h.029l-.018-.327-.023-.477q-.006-.262-.006-.482V46.28h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M83.375 41.107q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.757-.887-.244-.571-.244-1.333 0-.75.244-1.31.251-.565.757-.881.506-.315 1.273-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg fill=\"#3050f8\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M96.255 5.459h-.721l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V.56h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V.56h.578zM100.561 5.459h-.619V3.173h-2.513v2.286h-.613V.56h.613v2.072h2.513V.56h.619zM103.066 6.949h-1.944v-.3l.772-.779q.221-.221.371-.393.154-.175.233-.339.078-.168.078-.364 0-.243-.146-.368-.143-.129-.372-.129-.214 0-.378.075-.161.075-.329.207l-.193-.243q.172-.146.393-.246.225-.1.507-.1.411 0 .65.207t.24.575q0 .229-.097.432-.093.2-.264.397-.168.196-.393.418l-.614.603v.018h1.486z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M21.991 110.098h-.613v-4.9h2.733v.542h-2.12v1.738h1.995v.542h-1.995zM1.173 104.519H.56V99.62h2.732v.542H1.173v1.738h1.994v.542H1.173zM6.751 83.701h-.613v-4.899h2.733v.542h-2.12v1.738h1.995v.542H6.751z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m137.187 69.697 4.96-2.863M130.625 69.694l-4.958-2.862\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m71.071 46.909 3.382-1.953\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m77.835 43.004-3.382 1.952M81.116 37.188v-5.659\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M94.314 7.19v5.53M94.314 7.19v5.53\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m20.678 104.069-2.777-4.809M4.442 100.617l5.341-3.083M8.805 83.504l3.16 5.473\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m229.748 58.299-10.524-6.076M230.967 56.187l-10.524-6.076\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m229.748 58.299-5.262-3.038M230.967 56.187l-5.262-3.038\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"M220.443 51.519V40.2M220.443 51.519l-13.198 7.62M207.245 59.139l-13.198-7.62M194.047 51.519V40.2M194.047 51.519l-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M182.068 58.435v12.023M179.629 58.435v12.023\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M182.068 70.458v-6.011M179.629 70.458v-6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m180.849 59.139-9.923-5.729\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M235.901 59.136q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M222.702 36.276q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .923.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M227.009 38.729h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M196.306 36.276q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453M200.612 38.729h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M183.108 74.376q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.757 0-1.263-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M169.91 51.516q0 .756-.256 1.327-.256.566-.757.881-.5.316-1.244.316-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.501.31.757.875.256.566.256 1.328m-3.864 0q0 .923.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.535.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M164.829 53.969h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M220.443 40.2v5.659M220.443 40.2v5.659M194.047 40.2v5.659M194.047 40.2v5.659M170.926 53.41l4.961 2.865M170.926 53.41l4.961 2.865\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Fluvoxamine maleate","UNII":"5LGN83G74V"}],"Salts":["maleate"],"StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 148.145 110.658\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h149v111H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m147.107 63.97-9.92 5.727M130.625 69.694l-9.915-5.724M120.71 63.97l-13.198 7.62M107.512 71.59l-13.198-7.62M94.314 63.97l-13.198 7.62M81.116 71.59l-13.199-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M67.917 52.58v11.39M70.356 52.58v9.982\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M67.917 52.58v5.695M70.356 52.58v4.991\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m71.071 46.909 6.764-3.905M81.116 37.188V25.87M81.116 25.87l13.198-7.62M94.314 18.25V7.19M67.917 63.97l-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m54.719 71.59-13.203-7.629M52.281 72.997l-10.765-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m41.516 63.961-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.318 71.581.005 15.249M30.757 72.989l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.323 86.83 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m41.526 94.458 13.198-7.62M41.526 91.642l10.759-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.719 71.59.005 15.248M28.323 86.83l-13.199 7.62M15.124 94.45l5.554 9.619M15.124 94.45l-10.682 6.167M15.124 94.45 8.805 83.504\" class=\"bond\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M136.168 71.587q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M69.858 51.179h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732v2.738h-.565V46.28h.714l2.608 4.054h.029l-.018-.327-.023-.477q-.006-.262-.006-.482V46.28h.577z\" class=\"atom\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M83.375 41.107q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.757-.887-.244-.571-.244-1.333 0-.75.244-1.31.251-.565.757-.881.506-.315 1.273-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M96.255 5.459h-.721l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V.56h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V.56h.578zM100.561 5.459h-.619V3.173h-2.513v2.286h-.613V.56h.613v2.072h2.513V.56h.619zM103.066 6.949h-1.944v-.3l.772-.779q.221-.221.371-.393.154-.175.233-.339.078-.168.078-.364 0-.243-.146-.368-.143-.129-.372-.129-.214 0-.378.075-.161.075-.329.207l-.193-.243q.172-.146.393-.246.225-.1.507-.1.411 0 .65.207t.24.575q0 .229-.097.432-.093.2-.264.397-.168.196-.393.418l-.614.603v.018h1.486z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M21.991 110.098h-.613v-4.9h2.733v.542h-2.12v1.738h1.995v.542h-1.995zM1.173 104.519H.56V99.62h2.732v.542H1.173v1.738h1.994v.542H1.173zM6.751 83.701h-.613v-4.899h2.733v.542h-2.12v1.738h1.995v.542H6.751z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m137.187 69.697 4.96-2.863M130.625 69.694l-4.958-2.862\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m71.071 46.909 3.382-1.953\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m77.835 43.004-3.382 1.952M81.116 37.188v-5.659\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"M94.314 7.19v5.53M94.314 7.19v5.53\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m20.678 104.069-2.777-4.809M4.442 100.617l5.341-3.083M8.805 83.504l3.16 5.473\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":null,"Title":"Fluvoxamine","Treatment":"Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluvoxamine are known. (L1712)","UNII":"O4L1XPO44W","Wikipedia":"Fluvoxamine","XLogP":2.6}